StomTop patented devices are based on innovative intestinal sealing, are already in human clinical studies, and are addressing a market estimated at $3 billion annually.
StomTop devices are based on innovative internal intestinal sealing instead of adhesion to the abdomen skin, an impact development aimed to bring relief to millions of Ostomates (people having stoma). StomTop was established by Dr. Nurit Eyal and Dror Eyal, each having more than 30 years of experience in the biotechnology and life sciences industry.
We aim to support the ostomate community in a market of over 2 million cancer and inflammation patients and over $3B in revenue potential. We are targeting a short time to market and a potential deal with a major strategic partner.
SilTop, our first device, is ready for a First in Human clinical study to be started during Q2 2022. StomTop has a submitted broad patent covering the different aspects of our invention and its use.
The current annual market size is estimated at $3B with a CAGR of 5%. The high annual growth is coming from the rising number of colorectal and bladder cancer, inflammatory bowel disease, geriatric population, and living standards in developing countries.
With the funds from the current round, we are planning to take our first device through the process of clinical studies and regulatory market approval, to initiate the development of a device for urostomy, and develop next-generation devices for further ileostomy complications.
On the business side, based on our ongoing discussions with potential strategic partners, we could complete the first deal with one of the leading companies in the field. The potential exit may be from dividends out of substantial milestones payments, royalties, as well as from the acquisition of the company.
Update (6/6/2022): StomTop has just received approval for its first clinical study, beginning in 1 week. This is a key milestone for every health care company.